Abstract
Gastric cancer is an active topic of clinical and basic research with over 1 million new cases worldwide and a high morbidity and mortality rate. This disease is complex in nature because it arises from multiple interactions of genetic, local environmental, and host factors, resulting in biological heterogeneity. Indeed, most phase III clinical trials evaluating molecular drugs in gastric cancer failed. In the last decade onlyTrastuzumab, Ramucirumab and recently Nivolumab (targeting HER2, VEGFR2 and PD-1, respectively) are the only targeted therapies approved so far.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
